Lantern Pharma Inc (LTRN)

$3.08

+0.13

(+4.41%)▲

Market is closed - opens 8 PM, 25 Nov 2024

Performance

  • $2.80
    $3.21
    $3.08
    downward going graph

    9.09%

    Downside

    Day's Volatility :12.77%

    Upside

    4.05%

    downward going graph
  • $2.79
    $11.99
    $3.08
    downward going graph

    9.42%

    Downside

    52 Weeks Volatility :76.73%

    Upside

    74.31%

    downward going graph

Returns

PeriodLantern Pharma IncSector (Health Care)Index (Russel 2000)
3 Months
-33.76%
-7.3%
0.0%
6 Months
-50.56%
-0.5%
0.0%
1 Year
-23.61%
10.5%
0.0%
3 Years
-64.27%
8.8%
-24.0%

Highlights

Market Capitalization
31.8M
Book Value
$3.82
Earnings Per Share (EPS)
-1.78
Wall Street Target Price
20.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-28.07%
Return On Equity TTM
-44.82%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-19.5M
Diluted Eps TTM
-1.78
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.93
EPS Estimate Next Year
-1.61
EPS Estimate Current Quarter
-0.56
EPS Estimate Next Quarter
-0.59

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Lantern Pharma Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 565.58%

Current $3.08
Target $20.50

Technicals Summary

Sell

Neutral

Buy

Lantern Pharma Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Lantern Pharma Inc
Lantern Pharma Inc
-8.61%
-50.56%
-23.61%
-64.27%
-79.4%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-21.61%
-24.74%
-7.55%
13.66%
101.19%
Biontech Se
Biontech Se
1.94%
14.27%
14.47%
-63.37%
445.2%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-16.95%
63.94%
50.31%
30.85%
117.83%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.06%
0.04%
27.74%
141.35%
101.98%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Lantern Pharma Inc
Lantern Pharma Inc
NA
NA
NA
-1.93
-0.45
-0.28
NA
3.82
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.41
18.41
1.11
44.91
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.04
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.18
0.53
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Lantern Pharma Inc
Lantern Pharma Inc
Buy
$31.8M
-79.4%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$81.8B
101.19%
18.41
33.61%
Biontech Se
Biontech Se
Buy
$25.9B
445.2%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$31.8B
117.83%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.0B
101.98%
32.84
-4.51%

Insights on Lantern Pharma Inc

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 50.3% return, outperforming this stock by 73.1%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 30.9% return, outperforming this stock by 95.2%

Institutional Holdings

  • Vanguard Group Inc

    3.37%

  • CM Management, LLC

    1.72%

  • Goss Wealth Management LLC

    1.46%

  • Geode Capital Management, LLC

    0.80%

  • Renaissance Technologies Corp

    0.78%

  • Susquehanna International Group, LLP

    0.55%

Company Information

lantern pharma is leading a wave of innovation in cancer treatment that we believe will bring the best therapies to patients who are most likely to respond. we are pioneering precision medicine approach to cancer by tailoring promising drug programs to the right patients. our approach is to use biomarker based genetic screening to identify and treat patients that would benefit most from our drugs. we believe this approach will reduce the cost of development and increase the speed to market. our strategy is to acquire or partner with promising drug and diagnostic companies to move forward promising personalized medicine programs for cancer patients.

Organization
Lantern Pharma Inc
Employees
21
CEO
Mr. Panna Sharma PH.D.
Industry
Commercial Services

FAQs